Lupin Shifts Its Focus To Complexity With Biosimilars And Specialty Plans On Horizon
As It Reports Highest Margins And US Revenues In Five Years
While quarterly revenues show ups and downs in each region, Lupin is set on continued growth, with a touch of complexity and innovation – including shifting its thinking on the attractiveness of biosimilars.
